BRAND NAME
Xhance™

GENERIC NAME
Fluticasone propionate

MANUFACTURER
Optinose

DATE OF APPROVAL
September 18th, 2017

PRODUCT LAUNCH DATE
Second quarter of 2018

REVIEW TYPE
☐ Review type 1 (RT1): New Drug Review
   Full review of new chemical or biologic agents

☒ Review type 2 (RT2): New Indication Review
   Abbreviated review of new dosage forms of existing agents that are approved for a new
   indication or use

☐ Review type 3 (RT3): Expedited CMS Protected Class Drug Review
   Expedited abbreviated review of Centers for Medicare & Medicaid Services protected class
   drugs (anticonvulsants, antidepressants, antineoplastic, antipsychotics, antiretrovirals, and
   immunosuppressants)

☐ Review type 5 (RT5): Abbreviated Review for Intravenous Chemotherapy Agents
   Abbreviated review for intravenous chemotherapy agents which are usually covered under the
   medical benefit

FDA APPROVED INDICATION(S)
Treatment of nasal polyps in patients 18 years of age or older.

OFF LABEL USES
Not applicable

CLINICAL EFFICACY
Background

1 Q18 January – February

2

3
Nasal polyps are benign lesions of mucosa in the nasal sinus or cavity that consist of around 4% of the general population who are predominantly adults. Nasal polyps may be associated with allergy, asthma, aspirin sensitivity, cystic fibrosis, and allergic fungal sinusitis.

Therapy may include observation, medical or surgical treatments. The aim of treatment is to improve sinus drainage, restore olfaction and taste. Patients are typically treated in the primary care setting prior to surgery with an otolaryngologist.

The recommended treatment is to start with a topical nasal steroid in addition to treating the underlying cause or allergy.


<table>
<thead>
<tr>
<th>Study Design</th>
<th>A phase 3, randomized, double-blind, placebo-controlled study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient eligibility criteria:</td>
<td>• Eligible patients were at least 18 years of age and had chronic rhinosinusitis with nasal polyps (CRSwNP), with a polyp grade of 1 to 3 in each of the nasal cavities and moderate-severe symptoms of nasal congestion/obstruction at entry.</td>
</tr>
<tr>
<td>N</td>
<td>323</td>
</tr>
<tr>
<td>Drug Regimen</td>
<td>Xhance of 93 µg (n=81), 186 µg (n=80), 372 µg (n=80), and placebo (n=82) were given twice daily for 4 and 16 weeks.</td>
</tr>
<tr>
<td>Primary Outcome(s)</td>
<td>Co-primary endpoints:</td>
</tr>
</tbody>
</table>
| | • Reduction of nasal congestion and obstruction symptoms after week 4 from the “Average Diary Score, 7-day, Instantaneous AM”.
| | • Reduction in total polyp grade at week 16 from the nasal polyp grading score (0-3 per nostril, summed) via nasoendoscopy. |
| Secondary Outcome(s) | Key secondary endpoints (controlled for multiplicity): |
| | • Sino-nasal outcome test (SNOT-22) and Medical outcomes sleep study scale – revised (MOS-Sleep-R).
| | Other secondary endpoints: |
| | • Patient-reported nasal symptoms assessment.
| | • Objective endoscopic assessments of polyp grades.
| | • Quality of life (QoL) assessments
| | • Surgical intervention assessment.
| | • Medication evaluation questionnaire. |
| Results | Co-primary endpoints: |
| | • At week 4 (p<0.01) least squares (LS) mean change in congestion:
| | o Placebo (-0.24), 93 µg (-0.49), 186 µg (-0.54), 372 µg (-0.62)
| | • At week 16 (p<0.01) LS mean change in summed polyp grade:
| | o Placebo (-0.45), 93 µg (-0.96), 186 µg (-1.03), 372 µg (-1.06)
| | • Mean change in core symptoms score at week 4 (p-values): |
### Key secondary endpoints (controlled for multiplicity):
- At week 16, SNOT-22 improvement was substantial in all EDS-FLU and superiorly statistically significant compared to placebo (p<0.005).
- Patient-reported nasal symptoms assessment showed almost 2x proportional change in very much/much improvement compared to placebo (p<0.005).
- At week 16, percent change of >1 point improvement in polyp grade [p-value]:
  - Placebo (41%), 93 µg (56%) [N/A], 186 µg (66%) [<0.01], 372 µg (72%) [<0.001]
- At week 4, QoL was statistically significant in all EDS-FLU groups versus placebo.
- At week 16, percent change in surgical eligibility [p-value N/A]:
  - Placebo (-49%), 93 µg (-62%), 186 µg (-52%), 372 µg (-60%)

### # Withdrew due to Lack of Efficacy
A total of 14.6% in the placebo group, 93 µg (7.4%), 186 µg (11.3%), 372 µg (5.0%) in the Xhance group withdrew due to lack of efficacy.

### # Withdrew due to Adverse Effects
Not reported

### Study Design
A phase 3, randomized, double-blind, placebo-controlled study

### Patient eligibility criteria:
- Eligible patients were at least 18 years of age with CRSwNP with a polyp grade of 1 to 3 in each of the nasal cavities and moderate-severe symptoms of nasal congestion/obstruction

### N
323

### Drug Regimen
Xhance of 93 µg (n=81), 186 µg (n=80), 372 µg (n=82), and placebo (n=80) were given twice daily for 4 and 16 weeks.

### Primary Outcome(s)
Co-primary endpoints:
- Reduction of nasal congestion and obstruction symptoms after week 4 from the “7-day instantaneous AM average diary score”.

<table>
<thead>
<tr>
<th></th>
<th>Congestion/obstruction</th>
<th>Rhinorrhea</th>
<th>Facial pain or pressure</th>
<th>Sense of smell</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>-0.26</td>
<td>-0.23</td>
<td>-0.18</td>
<td>-0.04</td>
</tr>
<tr>
<td>93µg</td>
<td>-0.51 (&lt;0.01)</td>
<td>-0.48 (&lt;0.01)</td>
<td>-0.35 (N/A)</td>
<td>-0.23 (&lt;0.05)</td>
</tr>
<tr>
<td>186µg</td>
<td>-0.55 (&lt;0.01)</td>
<td>-0.55 (&lt;0.01)</td>
<td>-0.43 (&lt;0.01)</td>
<td>-0.21 (N/A)</td>
</tr>
<tr>
<td>372µg</td>
<td>-0.64 (&lt;0.001)</td>
<td>-0.55 (&lt;0.01)</td>
<td>-0.39 (&lt;0.01)</td>
<td>-0.33 (&lt;0.01)</td>
</tr>
</tbody>
</table>
### Secondary Outcome(s)

- Reduction in total polyp grade at week 16 from the nasal polyp grading score (0-3 per nostril, summed) via nasoendoscopy.
- Patient-reported nasal symptom assessments.
- Objective endoscopic assessments of polyp grades.
- QoL assessments.
- Surgical intervention assessment.
- Medication evaluation questionnaire.

### Results

**Co-primary endpoints:**
- At week 4 (p<0.001) least squares (LS) mean change in congestion:
  - Placebo (-0.24), 93 µg (-0.59), 186 µg (-0.68), 372 µg (-0.62)
- At week 16 (p<0.01) LS mean change in summed polyp grade:
  - Placebo (-0.61), 93 µg (-1.31), 186 µg (-1.22), 372 µg (-1.41)
- Mean change in core symptoms score at week 4 (p<0.05):

<table>
<thead>
<tr>
<th></th>
<th>Congestion/obstruction</th>
<th>Rhinorrhea</th>
<th>Facial pain or pressure</th>
<th>Sense of smell</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>-0.23</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.06</td>
</tr>
<tr>
<td>93 µg</td>
<td>-0.60</td>
<td>-0.58</td>
<td>-0.40</td>
<td>-0.28</td>
</tr>
<tr>
<td>186 µg</td>
<td>-0.71</td>
<td>-0.62</td>
<td>-0.51</td>
<td>-0.22</td>
</tr>
<tr>
<td>372 µg</td>
<td>-0.63</td>
<td>-0.58</td>
<td>-0.47</td>
<td>-0.27</td>
</tr>
</tbody>
</table>

**Secondary endpoints:**
- At week 16, SNOT-22 improvement was substantial in all EDS-FLU and superiorly statistically significant compared to placebo (p<0.001).
- Two-thirds of patient-reported nasal symptoms assessment showed very much/much improvement compared to 29% placebo (p<0.001).
- Proportion of patients with polyps eliminated in at least one nostril [p<0.05] all groups +372 µg EDS-FLU at week 24:
  - Placebo (8.7%), 93 µg (24.7%), 186 µg (24.6%), 372 µg (28.2%)
- At week 4, QoL was statistically significant in all EDS-FLU groups versus placebo.
- At week 16 percent change in surgical eligibility [p-value N/A]:
  - Placebo (-49%), 93 µg (-68%), 186 µg (-69%), 372 µg (-62%)

**# Withdrew due to Lack of Efficacy**
- A total of 12.5% in the placebo group, 93 µg (3.7%), 186 µg (5.0%), and 372 µg (0%) in the Xhance group withdrew due to lack of efficacy.

**# Withdrew due to Adverse Effects**
- Not reported

### CONTRAINDICATIONS

Xhance is contraindicated in patients with hypersensitivity to any of the ingredients.
CENTENE PHARMACY AND THERAPEUTICS
DRUG REVIEW
1Q18 January – February

BLACK BOX WARNINGS
Not applicable

DRUG INTERACTIONS
Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

ADVERSE REACTIONS
The most common adverse reactions (incidence 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DOSAGE AND ADMINISTRATION
- For intranasal use only. Xhance is delivered into the nose by actuating the pump spray into one nostril while simultaneously blowing into the mouthpiece of the device.
- Recommended adult dosage: One spray per nostril twice daily (total daily dose of 372 mcg). Two sprays per nostril twice daily may also be effective in some patients (total daily dose of 744 mcg).

PRODUCT AVAILABILITY
Nasal spray: 93 mcg of fluticasone propionate in each 106-mg with 120 metered sprays per device.

THERAPEUTIC ALTERNATIVES

<table>
<thead>
<tr>
<th>DRUG NAME</th>
<th>USAGE REGIMEN (route of admin/frequency of use)</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>mometasone furoate (Nasonex®)</td>
<td>2 sprays/nostril (50mcg/spray) twice daily (400 mcg/day)</td>
<td></td>
</tr>
<tr>
<td>fluticasone propionate (Flonase®)</td>
<td>200mcg (50mcg/spray) intranasally once or twice daily OR 400 mcg intranasally once or twice daily.</td>
<td>Off-labeled use.</td>
</tr>
<tr>
<td>budesonide (Rhinocort®)</td>
<td>128 mcg (32mcg/spray) intranasally once daily OR 400 mcg / day intranasally in 2 divided doses</td>
<td>Off-labeled use.</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Utilization Management Recommendation
There is not significant potential for inappropriate use.

Product Comparison
Equal therapeutic outcomes are anticipated for Xhance, mometasone furoate, fluticasone propionate, and budesonide nasal sprays; therefore, it would be clinically appropriate to provide equal access to all or to require a trial of one before the others.

Although not clinically required, it would be appropriate to limit the quantity of Xhance to 2 devices per 30 days.

REFERENCES


